Navigation Links
Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL)

ertex is conducting a global Phase 2b clinical development program for telaprevir consisting of three large clinical trials that are expected to enroll approximately 1,000 patients with HCV at clinical centers in the U.S., Canada and E.U. In February 2007, Vertex announced the initiation of PROVE 3, designed to enroll 440 genotype-1 HCV patients who have previously received interferon based therapy in the U.S., Canada and E.U. Vertex completed enrollment of 250 patients in the U.S.-based PROVE 1 trial in September 2006. The 320-patient, European-based PROVE 2 trial completed enrollment in January 2007. In these clinical trials, telaprevir is being dosed as 750 mg every 8 hours in combination with peginterferon alfa-2a (Pegasys(R)), both with and without ribavirin (Copegus(R)).

Vertex retains commercial rights to telaprevir in North America. Vertex and Tibotec are collaborating to develop and commercialize telaprevir in Europe, South America, Australia, the Middle East, and other countries. Vertex is collaborating with Mitsubishi Pharma to develop and commercialize telaprevir in Japan and certain Far East countries.

About Hepatitis C

Hepatitis C is a liver disease caused by infection with hepatitis C virus (HCV), which is also found in the blood of people with the disease. HCV, a serious public health concern affecting 170 million people worldwide, is spread through direct contact with the blood of an infected person. Though many people with hepatitis C may not experience symptoms, others may have symptoms late in the course of the disease such as jaundice, abdominal pain, fatigue and fever. Hepatitis C significantly increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and early death.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to com
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:10/30/2014)... Oct. 30, 2014 /CNW/ - Atlantic Canadians will save ... between Canada,s provinces and territories ... President of the Canadian Generic Pharmaceutical Association (CGPA), said ... while speaking at the Atlantic Summit on Healthcare and ... which is being hosted by the Public Policy Forum ...
(Date:10/30/2014)... 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... the Tel Aviv area of ... WuXi,s broad platform of integrated R&D services to local ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it ... Administration ("FDA") of the successful completion of an inspection ... first product to market.  Under the Company,s Consent Decree, ... and facilities are expected to be required before K-V ...
... Inc. Promote PurCotton(R) Brand in Shenzhen -- SHENZHEN, China, Sept. 10 /PRNewswire-Asia/ -- ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 2Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 3Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 4Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 5Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 6Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 7Winner Medical and U.S. Cotton Inc. Promote PurCotton(R) Brand in Shenzhen 8
(Date:10/31/2014)... 2014 — A team from the Broad Institute, ... of California, Santa Cruz, was awarded one of ... Pilot contracts with the goal of building a ... Cancer Genome Atlas (TCGA) and other datasets by ... in one cloud environment. This co-location will enable ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 At the ... about families narrowly escaping carbon monoxide poisoning in their ... just weeks away, one family-owned, Missouri-based heating and cooling ... to making sure families start the home heating season ... and secure. , Beginning Nov. 1, 2014, E ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Sleep apnea may make it hard ... parked your car or left your house keys, a small ... apnea showed that this ability -- called spatial memory -- ... sleep, even when other stages of sleep weren,t affected. REM ... typically occur. "We,ve shown for the first time that ...
(Date:10/31/2014)... device to give cancer researchers an unprecedented microscopic look ... through the body, causing more than 90 percent of ... cells travel, the device could uncover new ways to ... university,s Whiting School of Engineering and its Institute for ... system recently in the journal Cancer Research . ...
(Date:10/31/2014)... have found a drug combination that can trigger the ... way for new treatments, according to research that will ... Cancer Conference in Liverpool next week*. , When healthy ... of events culminating in self destruction. But cancer cells ... This means that cells grow out of control – ...
Breaking Medicine News(10 mins):Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... ... protective equipment, bad assumptions are hazardous and can result in injury -- or ... assumptions are widespread -- endangering both the effectiveness of occupational Hearing Conservation ... paper from Howard Leight, " Bad Assumptions about Hearing Protection ...
... , ... Dec. 1 Ovid, part of Wolters Kluwer Health and a ... information for the medical, scientific and academic markets, will be showcasing ... and the implementation of a new psychology lexicon, based on the ...
... , WASHINGTON, Dec. 1 The following is being ... Kerry, Ranking Member Lugar, and Members of the Committee. , ... serve as Administrator of the United States Agency for International ... the Agency. , Secretary of State Clinton has expressed ...
... The Patient Safety Authority Encourages Older Persons and Healthcare ... Upon Authority Data , HARRISBURG, Pa., Dec. 1 ... those 65 and older, including residents in nursing homes, according ... December Patient Safety Advisory . , According to the ...
... 30 November 2009. Performing surgical operations without leaving ... become a reality. This is demonstrated by the recent ... Surgery), an innovative surgical approach that allows surgical access ... advantageous for the patient: lack of scars, shorter hospital ...
... age are more likely to engage in risky health behaviors ... aging process may act as a disincentive to behave ,sensibly, ... in anticipation of ,miserable, old age. These findings 1 ... Queen,s University Belfast, Northern Ireland, are published online in Springer,s ...
Cached Medicine News:Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 2Health News:New White Paper Details Six Common Bad Assumptions About Hearing Protection 3Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 2Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 4Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 5Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 6Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 7Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 8Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 9Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 4Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 5Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 3Health News:Binge drinking youths find getting old a drag 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
... for aqueous samples of moderate viscosity and density. Proven ergonomic design reduces ... Volume Range (ul) ... 1.2~2.5 Imprecision(%) ... (ul) ...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: